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Abstract
Monitoring and evaluation of malaria control in pregnancy is essential for assessing the efficacy and
effectiveness of health interventions aimed at reducing the major burden of this disease on women
living in endemic areas. Yet there is no currently integrated strategic approach on how this should
be achieved. Malaria control in pregnancy is formulated in relation to epidemiological patterns of
exposure. Current emphasis is on intermittent preventive treatment (IPTp) during pregnancy with
sulphadoxine-pyrimethamine in higher transmission areas, combined with insecticide treated bed
nets (ITNs) and case management. Emphasis in lower transmission areas is primarily on case
management. This paper discusses a rational basis for monitoring and evaluation based on:
assessments of therapeutic and prophylactic drug efficacy; proportional reductions in parasite
prevalence; seasonal effects; rapid assessment methodologies; birthweight and/or anaemia
nomograms; case-coverage methods; maternal mortality indices; operational and programmatic
indicators; and safety and pharmacovigilance of antimalarials in pregnancy. These approaches should
be incorporated more effectively within National Programmes in order to facilitate surveillance and
improve identification of high-risk women. Systems for utilizing routinely collected data should be
strengthened, with greater attention to safety and pharmacovigilance with the advent of artemisinin
combination therapies, and prospects of inadvertent exposures to artemisinins in the first
trimester. Integrating monitoring activities within malaria control, reproductive health and
adolescent-friendly services will be critical for implementation. Large-scale operational research is
required to further evaluate the validity of currently proposed indicators, and in order to clarify
the breadth and scale of implementation to be deployed.
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Malaria in pregnancy is an immense public health prob-
lem with at least 50 million pregnant women living in
malaria endemic areas [1]. Under conditions of high
transmission there is increased Plasmodium falciparum par-
asite prevalence in placental and peripheral blood, which
is higher in first, compared to later, pregnancies. This epi-
demiological pattern for P. falciparum has been recognized
for many years, with higher prevalence in early pregnancy
which increases, if untreated, and then decreases as gesta-
tion progresses [2-4]. In stable high transmission areas,
almost all primigravidae, if unprotected, are likely to be
infected in early pregnancy and approximately half of
these would remain infected by the time of delivery if
untreated. In multigravidae, especially in higher parities,
prevalence is significantly reduced due to the acquisition
of parity-specific immunity [5]. Maternal HIV infection is
associated with increased P. falciparum prevalence and
delays clearance of parasitaemia in multigravidae.
Maternal anaemia and low birthweight are two of the
important consequences of malaria in pregnancy [6], and
Figure 1 illustrates the magnitude and importance of these
co-morbidities in primigravidae experiencing P. falci-
parum infection under stable endemic conditions. For
low, unstable transmission areas there are fewer studies,
but prevalence is greatly reduced (mostly <10%), fewer
primigravidae are exposed, and as a result there is reduced
development of parity specific immunity [6]. The longitu-
dinal pattern of Plasmodium vivax infection is less well
described, but is reported as more common in primigravi-
dae than in multigravidae in low transmission areas, and
as associated with poorer birth outcomes, such as reduced
birthweight and stillbirths [7,8].
Control strategies for malaria in pregnancy are formulated
in relation to these epidemiological patterns of infection,
with current emphasis in stable transmission areas on
intermittent preventive treatment (IPTp) during preg-
nancy combined with the use of insecticide-treated mos-
quito nets (ITNs) and case management while, in low
transmission areas, emphasis is primarily on case manage-
ment [1]. Increasing IPTp dosing from two to more fre-
quent doses may be beneficial in some circumstances, but
in view of increasing parasite resistance to sulphadoxine-
pyrimethamine (SP), the currently recommended antima-
larial for IPTp, appropriate monitoring, evaluation and
research is required in order to establish optimal control
strategies [9]. ITNs used throughout pregnancy, or from
mid-pregnancy onwards, improve pregnancy outcomes
particularly in the first few pregnancies in women living
under malaria endemic conditions in Africa and are rec-
ommended by WHO [10]. Their use is a pivotal control
option, although further research on their potential bene-
fits in women living in areas outside Africa and under con-
ditions of lower transmission is required. Current
recommendations for malaria control during pregnancy
in women living in areas with stable transmission are out-
lined in Figure 2[1].
Definitions of parameters related to efficacy and effective-
ness of current interventions for malaria control in preg-
nancy are outlined in Figure 3. These relate to the
assessment approaches which can be used and which are
discussed below.
A changing situation
The current global Roll Back Malaria target is that by 2010,
80% of all pregnant women in areas of high stable trans-
mission should receive IPTp. Although most countries in
sub-Saharan Africa have adopted this policy, only a small
number have achieved widespread programme imple-
mentation [11,12]. Although parasite resistance to SP
continues to increase it remains an effective strategy for
IPTp. Based on the systematic review by ter Kuile et al, SP-
ITPp was still effective at SP resistance levels from 19%–
26%, based on in vivo assessments in young children [13].
In view of the varied effectiveness of health systems
throughout Africa, these interventions in pregnancy must
be balanced against the need for effective monitoring and
surveillance programmes assessing progress with imple-
mentation (outputs), coverage (outcomes) and protective
efficacy (impact). An outline summary of currently rec-
ommended indicators for monitoring and evaluation of
programmes to control malaria in pregnancy is shown in
Venn diagram for malaria related pregnancy outcomes in 605 primigr vidaeFigure 1
Venn diagram for malaria related pregnancy outcomes in 605 
primigravidae. Data source: DELIMAL study, Burkina Faso (S. 
Gies et al, unpublished data and [34]).Page 2 of 12
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toring and evaluation programmes for malaria control in
pregnancy are poorly developed. Improved and extended
surveillance methods are needed as intervention pro-
grammes are more widely adopted and new antimalarial
drug options, including artemisinin-based combinations,
are introduced. With prompt feedback to programme
managers this should serve as a catalyst to improve deliv-
ery of interventions for malaria control in pregnancy.
Monitoring trends and continued evaluation will allow
prevention recommendations to evolve as the risk of
infection in women and effectiveness of antimalarial
drugs change. Demonstration of the burden of malaria
during pregnancy can then be used for directing national
malaria programme efforts. A further issue is that as effec-
tive strategies are rolled out, and transmission falls, coun-
tries with previously high transmission will need to adapt
their control strategies, for example, by reducing IPTp and
focusing on case detection, diagnosis and treatment.
To assess progress in the delivery of interventions for the
control of malaria in pregnancy, and their effectiveness, a
number of core indicators of process, outcome and
impact have been identified in order to guide national
programmes [14]. In this paper, some new indicators, are
reviewed as well as established assessment approaches, for
monitoring and evaluation of malaria control in preg-
nancy and the rational basis for their implementation.
Antimalarial drug efficacy
The Global Malaria Programme of the World Health
Organization (WHO) is developing a framework to mon-
itor and evaluate the efficacy and effectiveness of SP-ITPp
on pregnancy outcome in the context of SP resistance and
in the absence of continued SP testing in children which
previously has been used as a proxy for assessing resist-
ance. The mechanism of action of SP-based IPTp is not yet
well established, despite the widely advocated use of the
strategy in high transmission settings. SP, a long half-life
drug, is expected to be effective by both clearing malaria
infections and through post-treatment prophylaxis. For
monitoring SP efficacy for IPTp, both therapeutic and pre-
Definition of parameters for assessment of malaria control in pr g ancyFigure 3
Definition of parameters for assessment of malaria control in 
pregnancy.
1. Therapeutic drug efficacy:  elimination of asymptomatic
parasitaemia by Day 7 without recrudescence (ie recurrence
of the original parasites) within 42 days following
administration of IPTp.
2. Prophylactic drug efficacy:  duration of aparasitaemia in
pregnant women who are aparasitaemic at the time of
administration of IPTp.
3. Post-treatment prophylaxis:  suppression of new malaria
infections by residual antimalarial drug concentrations
following a treatment dose.
4. ITN protective efficacy:  duration of aparasitaemia in
pregnant women who are aparasitaemic at the time of
commencing use of an ITN.
5. Programme effectiveness:  reduction in adverse malaria-
related pregnancy complications due to one or more malaria
control interventions.
Recommended interventions for malaria control during preg-nancy for wome  living in areas with st ble transmissionFigure 2
Recommended interventions for malaria control during preg-
nancy for women living in areas with stable transmission. 
Source: World Health Organization [1].
1. A schedule of four antenatal visits, with three visits after
quickening (the first noted movements of the foetus). A visit in the
first trimester provides the opportunity to assess ITN use and to
deliver a bed net early in pregnancy
2. At least two separate doses of intermittent preventive treatment
with sulphadoxine-pyrimethamine in second and third trimester
given as a single dose under observation of a health worker. First
dose when foetal movements are felt (18-20 weeks gestation) and
the second a month later. HIV-positive women should receive
three doses or all women if HIV prevalence exceeds 10% and HIV
testing is not available
3. Insecticide-treated bed nets should be provided as early as possible
in pregnancy to all women, not only to those living in areas with
stable malaria but also to those living in epidemic and disaster
situations. The nets should be used throughout pregnancy and also
during the post-partum period.
4. Effective case management of malaria.
5. Screening for anaemia and iron supplementation for prevention and
treatment of anaemiaPage 3 of 12
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assessed.
There is a well-established standard methodology for
monitoring antimalarial therapeutic efficacy, which
involves repeated assessment of clinical and parasitologi-
cal responses to treatment during a fixed period of follow-
up in order to detect any reappearance of symptoms/signs
and/or parasites in the blood as an indication of reduced
sensitivity to a particular drug. There is currently no stand-
ard protocol for monitoring preventive efficacy, an impor-
tant component of IPT. Evidence suggests that re-
infections of falciparum malaria occur progressively ear-
lier as resistance intensifies, shortening the post-treatment
prophylaxis period [15]. Therefore, both the rate of re-
infection and duration of time-to-reinfection could be
useful indicators for measuring the preventive efficacy of
IPTp. These measurements should be related to the
desired outcomes of IPTp.
Figure 4 illustrates diagrammatically the reductions using
IPTp in proportional parasite burdens during pregnancy
in primigravidae in a transmission setting with an ento-
mological inoculation rate (EIR) of about 250 infective
bites/year. In these diagrams prevalence represents
peripheral parasitaemia. The reductions are estimated for
settings with high or low therapeutic and prophylactic SP
efficacy. For multigravidae, the parasite burdens would be
proportionally lower. With higher EIRs, e.g. 1,000 infec-
tive bites/year, then the cumulative incidence would be
up to four-fold higher. The patterns of re-infection in
these figures are estimated based on a half life of SP in
pregnancy of about seven days [16], which is shorter than
in non-pregnant women and using a two dose IPTp strat-
egy. Use of drugs with a shorter or longer half-life would
increase or decrease, respectively, the areas under the re-
infection curves. The sum of the areas under the preva-
lence curves indicates the overall burden of infection. This
illustrates the importance of the first half of pregnancy,
which is a period when current antimalarial interventions
have limited impact. This period is also not influenced by
uptake of ITNs at the first antenatal visit, which is often
after 20 weeks gestation. Poor control early in gestation
increases foetal loss and the risk of pregnancy anaemia.
Assessing the therapeutic efficacy response to the IPTp first
dose (IPTp × 1), can be achieved using the current stand-
ard WHO in vivo protocol [17], with the following modi-
fications: (i) pregnant women with asymptomatic
falciparum infections should be recruited as the study
group, (ii) clearance of the parasitaemias at a first antena-
tal visit in the second trimester, should be monitored, (iii)
a 42-day follow-up design should be used, with scheduled
visits on days 0, 3, 7, 14, 21, 28 and 42 following admin-
istration of IPTp first treatment, (iv) the second IPTp dose
would be given following completion of the 42-day fol-
low up, unless rescue treatment was required. According
to the WHO in vivo protocol [17], the duration of follow-
up for therapeutic efficacy is 28 days, and, as the recom-
mended interval between two IPTp doses is at least one
month, a 28-day follow-up is practical and logical. The
prophylactic effect of SP in infants has been shown to be
about 4–5 weeks and one might expect this to be longer
in pregnant women infected with parasites of the same
level of sensitivity because of the presence of some immu-
nity. For this reason, a 42-day follow-up should be
included.
Recrudescence should be differentiated from re-infection
through determination of msp1 and msp2 genotypes using
Table 1: Summary of WHO recommended indicators for monitoring and evaluation of programmes to control malaria during 
pregnancy.
Output indicators
1. Percentage of antenatal clinic staff (pre-service, in-service or at supervisory visits) trained in control of malaria during pregnancy in the past 12 
months (including IPT, counselling on ITN use and case management for pregnancy women).
2. Percentage of health facilities reporting stock-out of the recommended drug for IPT (currently sulphadoxine-pyrimethamine) in the past 
month.
Outcome indicators
3. Percentage of pregnant women attending antenatal care who receive IPT under direct observation (first dose, second dose, third dose).
4. Percentage of pregnant women who report having slept under an ITN the previous night.
Impact indicators
5. Percentage of low birth-weight singleton live births (< 2500 g), by parity.
6. Percentage of screened pregnant women with severe anaemia (haemoglobin 7 g/dl) in third trimester 7, by gravidity.
Source: World Health Organization [14].Page 4 of 12
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dihydrofolate reductase (pfdhfr) and dihydropteroate syn-
thase (pfdhps) genes. Characterization of these resistance
molecular markers would provide additional information
on SP resistance and should be assessed.
Post-treatment prophylaxis could be measured using the
above approach assessing the occurrence of new falci-
parum infections and time to re-infection in uninfected
pregnant women within 42 days following administra-
tion of IPTp. This could be measured either in previously
untreated, aparasitaemic pregnant women, or in women
who were parasitaemic and had cleared the parasites after
the first SP dose. Either of these options would be suita-
ble, but assessment should not include a combination of
both. The proportional reduction in parasite prevalence
between the time when IPTp × 1 is received until delivery
is an assessment of both therapeutic efficacy and post-
treatment prophylaxis. With more frequent IPTp doses
this indicator provides an estimate of the total post-treat-
ment prophylaxis effect. This would be a useful composite
indicator of both drug resistance and prophylactic efficacy
in women receiving IPTp.
Seasonal effects
What are the monitoring and evaluation implications of
malaria seasonality?
Low EIRs during the dry season do not necessarily equate
to low placental parasitaemia. Estimates of dry season
prevalence are only slightly lower than those in the wet
season [18]. Figure 5 illustrates the influence of season
and SP-IPTp efficacy on parasite prevalence, assuming
prevalence is marginally lower during the dry season. In
the examples shown, ITN use from the time of first ante-
natal visit (e.g. from five months) would offer small addi-
tional protection, which would be greater in the wet
season. Figure 5c illustrates that ITN use prior to preg-
nancy would significantly reduce peripheral parasite prev-
alence during the first five months of pregnancy, critically
Influence of high and low therapeutic or prophylactic efficacy on parasite burden in primigravidae in high transmission settingsFigure 4
Influence of high and low therapeutic or prophylactic efficacy on parasite burden in primigravidae in high transmission settings. 
(A) Parasite prevalence in primigravidae (PG) and multigravidae (MG) in unprotected pregnancies (from [2]). The fall in para-
site prevalence after four months gestation corresponds to the decline observed if untreated and is related to the development 
of parity-specific immunity; (B) High therapeutic (100%) and low prophylactic efficacy (50%) with two dose SP-IPTp intermit-
tent preventive treatment; (C) High therapeutic (100%) and high prophylactic efficacy (100%); (D) Low therapeutic (50%) 
and low prophylactic efficacy (50%).Page 5 of 12
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emphasizes the importance of assessing net use by, and
availability to non-pregnant women as an indicator of
adherence prior to pregnancy. It also suggests that strate-
gies proposing use of IPTp in the wet season alone would
be a disadvantage to primigravidae experiencing their first
trimester in the wet season. These women would not
receive IPTp in the wet season, as they are first trimester
pregnancies, and then, despite a significant parasite bur-
den, would not receive IPTp during the dry season with a
seasonal implementation strategy. Protection with ITNs
prior to pregnancy would be required to reduce their risk
of first trimester infections. The addition of a new indica-
tor for ITN coverage and use in non-pregnant adolescents
is of particular importance in view of any impending first
pregnancy.
Programme effectiveness
Rapid assessment methodology
A methodology for this has been published based on
cross-sectional prevalence assessments of maternal parasi-
taemia, maternal anaemia (Hb <11.0 g/dl for moderate
anaemia and <7.0 g/dl for severe anaemia) and low birth-
weight (<2,500 gms), categorized by gravida class [19].
These indicators significantly improve with use of SP-IPTp
and/or ITNs [20,21]. Sentinel surveys monitoring these
parameters are important for baseline surveys as well as
for evaluating subsequent interventions. A slightly higher
haemoglobin cut-off, indicating moderately severe anae-
mia (Hb < 8.0 g/dl), has been frequently used in preva-
lence assessments and has the advantage that it may be
more sensitive to malaria-related changes in haemoglobin
concentration in pregnant women living under stable
transmission conditions [22].
Influence of seasonal effects and ITN use prior to pregnancy on parasite burden in primigravidae (PG)Figure 5
Influence of seasonal effects and ITN use prior to pregnancy on parasite burden in primigravidae (PG). (A) First trimester 
occurring during the wet season and two dose SP-ITPp prescribed in dry season; (B) First trimester in the dry season and two 
dose SP-ITPp prescribed in wet season; (C) Good ITN adherence prior to and during first trimester in dry season with subse-
quent two dose SP-ITPp in wet season. The Entomological Inoculation Rate (EIR) is assumed to be approximately 20/month in 
the wet season and <5/month in the dry season.Page 6 of 12
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Approaches for measuring programme effectiveness using
routinely collected data should also be considered. Two
methodologies have been assessed, based on nomograms
for anaemia [22] or birthweight [23], which utilize rou-
tinely collected data. Evaluation of birthweight indicators
has shown their utility for monitoring malaria exposure
and control [24,25], and as birthweight is routinely meas-
ured in most delivery facilities, standardization of meas-
urement should allow effective use of nomograms for
monitoring. Figure 6 illustrates the use of the birthweight
nomogram for evaluation of outcomes of several hundred
singleton pregnancies for women delivering in health cen-
tres in areas randomized to receive either IPTp-SP alone,
or IPT-SP combined with an extended SP health promo-
tion campaign. These data were made available through
the DELIMAL study conducted in Burkina Faso between
2004 and 2006 (S.Gies, unpublished data). SP-IPTp was
not introduced until April 2004, so that 2002–2003 and
part of 2004 were collected under the previous weekly
chloroquine prophylaxis policy. In both study arms,
birthweight nomograms improve with a directional flow
towards reduced low birthweight prevalence (y axis) and
lower odds ratios (x axis) with increasing duration of both
interventions. There is fluctuation in the indicators
between years and the incremental changes are not
sequential, although the general direction of change with
time is towards improved birth outcomes. Review of these
indicators over 3–5 year intervals should demonstrate
changing trends.
Maternal anaemia has also been proposed as an indicator
for monitoring malaria control in sub-Saharan Africa
[26], based on the excess of risk of anaemia in primigravi-
dae compared to multigravidae. This difference is usually
observed at first antenatal clinic attendance in women liv-
ing in malarious areas. An anaemia nomogram has been
developed to assess changes in this excess risk with altered
malaria exposure [26]. This requires systematic evaluation
in view of its combined utility for use in antenatal clinics
as well as for monitoring malaria control in pregnancy. It
provides a standardized assessment format for compara-
tive evaluations. Sensitivity and specificity estimates are
good using either moderate (Hb <11.0 g/dl), or severe
anaemia (Hb <8.0 g/dl), for the cut-off values [26].
A key issue is the quality and frequency of assessment of
antenatal haemoglobin in most countries in sub-Saharan
Africa. This is becoming an increasingly important issue in
view of the sustained, high prevalence of anaemia, often
severe, in women living in malarious areas and which is
not attributable to iron deficiency alone [22,27]. Screen-
ing, recognition and appropriate management of preg-
nancy anaemia is a pivotal aspect of antenatal care and
strategies of assessment should be more effectively linked
to the monitoring of malaria control in pregnancy. The
WHO currently recommends screening for anaemia in
pregnancy [14].
Case coverage method
The screening method used for estimating vaccine efficacy
has been applied recently as a surveillance tool for esti-
mating drug effectiveness of SP-IPTp in reducing either
low birthweight or anaemia prevalence during pregnancy
[28]. The case-coverage method requires birthweight,
anaemia, or placental malaria data and knowledge of fre-
quency of use of SP-IPTp during pregnancy. It also has
potential utility for estimating ITN effectiveness, provid-
ing data on ITN coverage in pregnant women is available
and the frequency with which women use ITNs.
Maternal mortality
This is an important complication of malaria in preg-
nancy and in lower transmission settings may result
directly from severe malaria [29], or in higher transmis-
sion areas, indirectly, from severe anaemia [30]. With
improved malaria control, maternal mortality indicators
should improve and show reduced seasonal variation. As
mortality indicators are routinely collected in many
regions, there is a need for surveillance methodologies
linking them to malaria intervention strategies and which
allow seasonal analyses. Large sample sizes are needed for
these analyses and population-based demographic health
surveillance databases would be suitable.
Annual birthweight indicators for singleton pregnancies reported by DELIMAL health centres in Burkina Faso b twe n 2002–2006 (pr -intervention, and intervention pril 2004–2006)Figu e 6
Annual birthweight indicators for singleton pregnancies 
reported by DELIMAL health centres in Burkina Faso 
between 2002–2006 (pre-intervention, and intervention 
April 2004–2006). Point values indicate the year of data col-
lection. The odds ratio refers to excess low birthweight 
(<2500 g) prevalence in primigravidae compared to multi-
gravidae. Areas receiving SP-ITPp intervention alone (■); 
areas receiving SP-ITPp combined with a pregnancy health 
promotion campaign (●).Page 7 of 12
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In order to improve access to antimalarial interventions
targeting pregnant women, Reproductive Health Pro-
grammes are central to effective implementation. The
high rate of antenatal attendance of at least two visits
reported in sub-Saharan Africa is encouraging as an entry
point for reaching pregnant women with antimalarial
interventions. The gestational age of first visit and attend-
ance of adolescents are two issues, which influence the
effectiveness of programmes. This is because the burden
of malaria in pregnancy is higher with late attendance as
the intervention comes too late in pregnancy; also adoles-
cents are the highest risk group due to both their young
age and nulliparity. Adolescents living in malarious areas
have poorer pregnancy outcomes compared to older
women [31,32], and identification and evaluation of indi-
cators in this vulnerable group is an important aspect of
malaria control. There is also evidence in adolescent girls
of a partial reversal during puberty of age-dependent
malaria immunity (G. Kalanda, personal communica-
tion).
Although collection of antenatal attendance indicators is
important, high attendance does not necessarily translate
into high IPTp coverage [33] and updated information on
SP-IPTp and ITN coverage and use among pregnant
women living in high malaria transmission areas is essen-
tial to ensure that women in remote areas are accessing
antimalarial interventions. Distance indicators should
also be considered. There is evidence from rural Tanzania
that mean birthweight for dispensary deliveries is associ-
ated with distance from the main district hospital, with
deliveries occurring at 25 km or greater distances at high-
est risk for low birthweight [24]. ITPp was not imple-
mented effectively in these rural districts and women
further away from the main town may have received less
health education regarding the consequences of malaria
in pregnancy and had fewer opportunities for referral.
Strategies promoting SP-IPTp and ITN use for pregnant
women are required. Indicators of health promotion
activities through existing services should be assessed in
areas of low coverage of interventions with a view to
developing promotional activities targeted to pregnant
women. There is evidence that these campaigns can lead
to major increases in coverage [34], particularly as, even
with knowledge of malaria in pregnancy, women also
may express concerns that antimalarials have adverse
effects on their baby and as a result can show reluctance to
purchase these drugs [24]. Linked to this is the need for
indicators of staff training, as well as research on the use
of teaching aids, including diagrams which can be used as
examples to show malaria burden estimates as illustrated
in Figures 3 to 6.
Monitoring safety of antimalarials
Monitoring the safety of antimalarial drugs during preg-
nancy is an essential part of public health programmes.
WHO recommends the integration of pharmacovigilance
in public health programmes to ensure their acceptance
and effectiveness [35]. Evidence on the safety of drugs
implemented by national malaria control programmes
has the potential to increase programme success by pro-
viding guidance on reducing the risks of adverse reactions
thereby increasing overall public trust. Furthermore, com-
paring the risk-benefit profiles of different antimalarial
drugs would allow evidence-based decisions to be taken
on the most effective as well as safer and better tolerated
interventions. Adverse drug reactions, particularly serious
adverse events affecting pregnancy outcomes (such as
pregnancy loss or congenital anomalies) or severe skin
reactions, can have serious public health impact and spoil
confidence in any national programme. This can also lead
to poor adherence, which in turn can result in treatment
failure and increase the risk of development of parasite
resistance leading to reduced efficacy.
Most countries in sub-Saharan Africa have little infrastruc-
ture and few resources for routine pharmacovigilance and
very few have a formal system for routine collection of
data on possible drug-related adverse effects [36,37]. The
extrapolation of safety data derived from industrialised
countries is limited by the type of drugs used in countries
with established pharmacovigilance systems (i.e. with
sparse experience of drugs for tropical diseases), the
underlying differences in populations in terms of genetic
make up, diet and health-seeking behaviour. Addition-
ally, high levels of co-morbidities and concomitant medi-
cation use (such as for HIV, TB, malaria and other
infections), as well as the use of traditional remedies in
developing countries can increase the risk of drug interac-
tions and adverse reactions. The concern is great for vul-
nerable groups like pregnant women. There is often
limited information on the safety of drugs in this group as
pregnant women are systematically excluded from pre-
licensure clinical trials out of concern for not harming the
mother or her unborn baby.
The process of establishing risk or safety of drugs used in
pregnancy requires special considerations and involves
the systematic recording of data on drug exposure and
pregnancy outcomes. One of the most established
approaches is the "Pregnancy Exposure Registry", a pro-
spective, observational study monitoring outcomes of
pregnancies exposed to specific drugs. This approach
requires significant resources, but can be time-limited
[38]. Much attention has been given to the establishment
of an international antimalarial exposure registry due the
widespread implementation of artemisinin combination
therapies (ACTs) as first-line therapies in Africa and the      Page 8 of 12
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1. Birthweight and anaemia Targets Tools Research
Low birthweight and maternal 
anaemia prevalence (Hb <10 g/dl 
and <8 g/dl) by parity
Reduced prevalence of low 
birthweight and anaemia
Rapid assessment methodologies; 
annual hospital wet season surveys
Birthweight and anaemia 
nomograms; annual trends and 
changes with new interventions
Malaria prevalence at delivery Zero prevalence Health facility surveys Use of rapid diagnostic tests
2. Maternal mortality Declining maternal mortality rates Demographic health surveys and 
hospital case fatality rates
Seasonal mortality patterns and 
severe anaemia and malaria 
mortality rates
Table 2: Monitoring and evaluation indicators, tools and assessment methods: output indicators.
Indicator Targets Tools Research
1. SP-IPTp coverage
Proportion of pregnant women 
with two SP-IPTp treatments in 
women delivering at health 
facilities or with home deliveries
80% of pregnant women receive 
IPTp in stable transmission areas
Health facility surveys and health 
promotion assessments
Missed opportunities; health 
promotion assessment; use of new 
promotion tools
2. ITN coverage
Proportion of pregnant and non-
pregnant women with ITNs, 
properly deploying (adherence) 
and properly treated with 
insecticides
100% of pregnant women at risk 
from malaria are protected
Health facility and community 
surveys; health promotion 
assessments
Missed opportunities; promotion 
assessment; use of new promotion 
tools
Proportion of adolescents 
deploying ITNs
100% coverage. New indicator Female adolescent friendly health 
services (AFHS)
Evaluation of AFHS incorporating 
malaria control activities
Proportion using ITNs prior to 
first pregnancy
100% coverage. New indicator Household surveys Periodic cross-sectional surveys
3. Proportion of pregnant 
women diagnosed and 
promptly treated with 
recommended drug
All malaria patients correctly 
diagnosed and treated
Hospital surveys and case fatality 
rates
Adherence to first-line therapy
4. Staff training
Proportion completing training 
programme
All ANC and malaria programme 
staff
Training programme Curriculum content and feedback; 
use of diagrams illustrating malaria 
burdenPage 9 of 12
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a need to establish simple but effective pharmacovigilance
systems to detect early signals of any major teratogenic
effect associated with a prenatal exposure to antimalarial
drugs. Such safety issues could have serious consequences
for public health, and successful implementation of the
recommended strategy for malaria in pregnancy requires
reliable safety profiles for antimalarial drugs in use in
order to inform policy makers, national malaria control
programmes and health care providers. This will require
close and effective collaboration between the different
stakeholders (including policy makers, pharmacovigi-
lance experts, the pharmaceutical industry and health care
providers)[40]. Safety monitoring will assist in achieving
the goals of national malaria control programmes and is
thus an important indicator to be included in a monitor-
ing and evaluation strategy.
Table 4: Monitoring and evaluation indicators, tools and assessment methods: programmatic indicators.
Indicator Targets Tools Research
1. Identification of high risk 
individuals
Proportion of adolescent ANC 
attendees
>80% of adolescents attending 
ANC
Health facility assessments Strategies for delaying pregnancies
Proportion of primigravidae with 
late ANC attendance
<10% attendees Health facility assessment Reasons for late attendance
Distance indicators of household 
residence from main health facility
Identification of high risk areas Household surveys Community SP-IPTp distribution
Antenatal HIV infection Prevalence reduction Mother to child HIV transmission 
assessments
Implementation of HIV prevention 
strategies
2. Antimalarial drug efficacy 
estimates
Antimalarial therapeutic efficacy Agreed surveillance interval 
(2–5 years)
Antimalarial in vivo sensitivity tests Comparative drug evaluations
Proportional reduction in 
parasitaemia between first 
antenatal visit and delivery
New indicator Health facility prevalence estimate Comparison with birthweight or 
anaemia outcomes
Proportion of women with 
placental infection who have 
received two SP-IPTp doses
Assessment in sentinel health 
facilities
Case-coverage methodology for 
determining SP-ITPp efficacy
Comparison of case-coverage 
efficacy estimates method with in 
vivo tests
Antimalarial post-treatment 
prophylaxis
Agreed surveillance interval 
(2–5 years)
Antimalarial prophylactic efficacy 
tests
Evaluation in aparasitaemic women 
on IPTp
3. Safety indicators
Inadvertent antimalarial drug 
exposure in first trimester
No exposures in asymptomatic 
women
Cross-sectional household/health 
facility surveys
Prevalence estimates and 
associated pregnancy outcomes
Assessment of safety indicators via 
national and international 
antimalarial exposure registry
Establishing functional registry Standardized protocol under 
development by WHO
Demonstration sites; new 
methods for drug exposure, 
ascertainment, congenital anomaly 
detectionPage 10 of 12
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The indicators and assessment methodologies discussed
in this review are summarized in Tables 2, 3, 4, which also
include a summary of research priorities related to their
evaluation. Although there is substantial evidence of the
utility of some of these, there are few control programmes
systematically using indicators for monitoring and evalu-
ation of malaria control in pregnancy, largely due to a lack
of investment, training and capacity. There are agreed
research priorities to evaluate safe and effective drugs to
treat malaria in pregnancy which include: identifying new
drugs to replace sulphadoxine-pyrimethamine for IPTp;
evaluating the optimum combinations of control meas-
ures in different epidemiological settings; ways for scal-
ing-up use of ITNs and SP-IPTp [41]; and assessing the
awareness of health workers on the risks of inadvertent
treatments in the first trimester [42]. In parallel with these
efforts, there is a need to introduce standardized monitor-
ing and surveillance activities in pregnancy within
national control programmes in order to ensure interven-
tions remain effective when implemented on a program-
matic basis.
Whilst challenging, an effective partnership between the
Ministries of Health and local research institutions is
essential. The Ministry of Health could provide the neces-
sary framework for routine health system data collection
on the one hand (for output and outcome indicators),
and research institutions and other partners providing the
expertise for monitoring drug efficacy and programme
effectiveness. Additional partners would be required to set
up effective safety monitoring, such as policy makers and
the pharmaceutical industry.
Tables 2, 3, 4 outline the tools available, and where and
how each of the proposed indicators are collected,
through health facilities, household surveys, sentinel sur-
veillance or national monitoring. The frequency of collec-
tion of this information in part depends on the level of
malaria exposure which women experience. This relates to
their disease burden and levels of drug resistance, and also
on the cost, level of complexity of the survey method, and
whether the data would be collected through the health
system or by separately conducted research studies. The
translation of research findings into effective program-
matic activities requires this on-going surveillance at these
different levels. This should also ensure the equitable dis-
tribution of interventions to higher risk groups. Monitor-
ing indicators should also be incorporated within relevant
research studies in order to facilitate relating research
study findings to concurrent programme evaluations.
Systematic monitoring should be co-ordinated at national
and regional levels to facilitate summary analyses of basic
indicators. Surveillance should encourage the formula-
tion of appropriate databases, which could be updated
with routinely collected pregnancy data. Data linkage
would allow assessment of trends for seasonal indicators,
allowing their utility to be assessed under changing epide-
miological conditions. With increasing efforts towards the
global eradication of malaria there is an urgent need for
strengthening health management information systems
for improved measurement and surveillance of control
interventions in general, including special risk groups
such as pregnant women and adolescents.
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